Clinical trials: SARS-CoV2
Moderate COVID-19 Pneumonia, Severe COVID-19 Pneumonia, Pneumonia, Viral
COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients
Due to the limitations of COVID-19 treatment and in the absence of licensed antiviral for COVID-19, the historical choice of therapeutic convalescent plasma (CP) is considered especially against RNA viruses .It was known that…
- Trial name
- NCT04474340
- Testing
- COVID-19 Convalscent Plasma
- Where
- Kuwait
- Volunteers
- 300 people
- Sponsor
- Ministry of Health, Kuwait
Covid-19
COVID-19 Virtual Care at Home
This multicentre prospective cohort trial is designed to demonstrate effectiveness and efficiency of a virtual care model for the management of COVID-19 patients isolating at home.
- Trial name
- NCT04420182
- Testing
- Virtual Care at Home
- Where
- 5 sites in Canada
- Volunteers
- 817 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
COVID-19
PROLIFIC ChemoprophylaxisTrial (COVID-19)
The number of confirmed cases of COVID-19 infectious disease arising from the SARS-CoV-2 coronavirus is rising substantially and rapidly, with the potential to overwhelm the ability of the entire National Health Service (NHS) to…
- Trial name
- NCT04352933
- Testing
- Hydroxychloroquine - Daily dosing, Hydroxychloroquine - Weekly Dosing
- Where
- United Kingdom
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Covid19
Covid-19 Rapid Diagnostic Tests on Blood Drop
This study will evaluate the diagnostic reliability of the Biosynex rapid blood test for Covid-19 infection.
- Trial name
- COVID-TEST (NCT04467008)
- Where
- France
- Volunteers
- 113 people
- Sponsor
- CMC Ambroise Paré
Covid19, Depression
Depression and Anxiety in Long Term Coronavirus Disease COVID-19
Background : Depression and Anxiety are linked to COVID (Coronavirus Disease)-19 long-term impact through several mechanisms. The possible way is the alteration of neurotransmitter regulation from the interaction of severe acute…
- Conditions
- Covid19, Depression, Anxiety
- Trial name
- DALT-COV (NCT04893668)
- Testing
- Depression, Anxiety
- Where
- Indonesia
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Hasanuddin University
SAR-CoV-2, Cellular Immune Response
Study of Immune Response in Subjects Vaccinated Against SARS-CoV-2 Infection
Twelve months after the first SARS-CoV-2 cases in Wuhan, the FDA approved the first COVID-19 vaccine (Pfizer-BioNTech). Early studies on healthcare workers showed that antibody levels, especially against the Spike protein…
- Conditions
- SAR-CoV-2, Cellular Immune Response, Antibody Response
- Trial name
- BioVAC-immunit (NCT07049497)
- Testing
- Evaluation of the T cell response in terms of IFN-γ measured by ELISpot
- Where
- Italy
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Kidney Transplantation, SARS-CoV-2 Acute Respiratory Disease
Safety and Immunogenicity of 2-dose Inactivated COVID-19 Vaccine in Kidney Transplant Recipients
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has a major impact on transplant recipients, with mortality rates up to 20%.
- Conditions
- Kidney Transplantation, SARS-CoV-2 Acute Respiratory Disease, Vaccine
- Trial name
- NCT04969614
- Volunteers
- 300 people
- Sponsor
- West China Hospital
Covid19, SARS-CoV Infection
COVID-19 IgG Formation in Physicians at ALGH and Their Household Members
This study is a community hospital-based study that will enhance information being obtained in similar studies taking place in France, Denmark, and China.
- Conditions
- Covid19, SARS-CoV Infection, Communicable Disease
- Trial name
- NCT04540484
- Testing
- Screening
- Where
- United States
- Volunteers
- 507 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Coronavirus Infections
The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection
The study explores the efficacy of lopinavir plus ritonavir and arbidol in treating with novel coronavirus infection. As a result this study would provide evidence for the clinical usage of these drugs in the future .
- Trial name
- ELACOI (NCT04252885)
- Testing
- Lopinavir and Ritonavir Tablets, Arbidol
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Guangzhou 8th People's Hospital
COVID-19, SARS-CoV-2
Efficacy and Safety of JS016 in Patients With SARS-CoV-2 Infection (COVID-19)
The human monoclonal antibody CB6 showed potent neutralization activity in vitro against SARS-CoV-2. CB6-LALA (also called JS016) has been developed for clinical use.
- Trial name
- NCT04931238
- Testing
- JS016
- Where
- 4 sites in China
- Volunteers
- 200 people
- Sponsor
- Peking Union Medical College Hospital
Corona Virus Infection
COVID-19 Antigen Rapid Test Evaluation in Low-Prevalence Setting
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting COVID-19 pandemic present important diagnostic challenges.
- Trial name
- CV006 (NCT05911074)
- Testing
- The Abbott Panbio™ COVID-19 Ag Rapid Test
- Where
- Botswana
- Volunteers
- 7,274 people, healthy volunteers welcome
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
COVID19
Characteristics of Critically Ill COVID 19 Patients
COVID19 is n outbreak with unpredictable outcome
- Trial name
- NCT04465058
- Testing
- COVID19
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Assiut University
COVID-19
Seroprevalence of Infection-induced SARS-CoV-2 Antibodies (COVID-19) in Children
It is unknown what proportion of children have been exposed to SARS-CoV-2 and how many have antibodies among children seeking medical care for non-Covid-19 related conditions.
- Trial name
- NCT05358626
- Testing
- SARS-CoV-2 IgG Antibody testing
- Where
- Vietnam
- Volunteers
- 4,032 people
- Sponsor
- National Children's Hospital, Vietnam
COVID-19 Pandemic, Diabetes
Study on the Effect of Incentive Spirometer-based Respiratory Training on the Long COVID-19
The COVID-19 pandemic has emerged as the most significant public health crisis of the 21st century. As of the end of January 2023, global confirmed cases have exceeded 670 million, with a domestic cumulative total of 10.24…
- Conditions
- COVID-19 Pandemic, Diabetes, Hypertension, Cardiac Disease
- Trial name
- NCT06231225
- Testing
- Incentive Spirometer respiratory training
- Volunteers
- 100 people
- Sponsor
- National Taipei University of Nursing and Health Sciences
SARS-CoV-2
Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021
This is an open-label study enrolling healthy adults that participated in Study ARCT-021-01 (the Parent Study). Participants will receive either a single injection of ARCT-021 or no injection and be followed for up to 365 days.
- Trial name
- NCT04728347
- Testing
- ARCT-021
- Where
- Singapore
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
COVID-19
Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination
Bacillus Calmette-Guérin (BCG) vaccine not only protects against tuberculosis, but has also been shown to induce protection against various infections with a viral aetiology, leading to significant reductions in morbidity and…
- Trial name
- NCT04417335
- Testing
- BCG vaccine
- Where
- 2 sites in Netherlands
- Volunteers
- 2,014 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Covid19
Characterisation of the Immune Response to SARS-CoV-2 / COVID-19
Emerging clinical details of the current SARS-CoV-2 pandemic have illustrated that there are multiple clinical presentations and outcomes of this viral infection.
- Trial name
- NCT04729452
- Testing
- blood test
- Where
- United Kingdom
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Cwm Taf University Health Board (NHS)
SARS-CoV-2 Acute Respiratory Disease, SARS-CoV-2 Sepsis
The Corona Study of Middle Norway
CUT COVID is a cohort study establised to collect information on patients hospitalized because or with infection by SARS-CoV-2. The cohort data includes clinical data and biological samples from multiple timepoints during…
- Conditions
- SARS-CoV-2 Acute Respiratory Disease, SARS-CoV-2 Sepsis, SARS CoV 2 Infection
- Trial name
- CUT COVID-19 (NCT05638178)
- Testing
- No intervention
- Where
- 5 sites in Norway
- Volunteers
- 223 people
- Sponsor
- St. Olavs Hospital
COVID-19
Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)
This study is a randomized, double-blinded, and placebo controlled phase Ⅰ/Ⅱ clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT04352608
- Testing
- Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule, Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule, Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
- Where
- China
- Volunteers
- 744 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
COVID-19
Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)
The purpose of the study is to determine if Liquid Alpha1-Proteinase Inhibitor (Human) (Liquid Alpha1-PI) plus SMT can reduce the proportion of participants dying or requiring intensive care unit (ICU) admission on or before Day…
- Trial name
- NCT04547140
- Testing
- Liquid Alpha1-Proteinase Inhibitor (Human), Standard Medical Treatment
- Where
- 20 sites in United States, Brazil and 3 more
- Volunteers
- 57 people
- Sponsor
- Grifols Therapeutics LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.